精品文档---下载后可任意编辑DEK 原癌基因在新辅助化疗前后宫颈癌组织中的表达及临床意义的开题报告摘要宫颈癌是妇女最常见的恶性肿瘤之一，新辅助化疗已经成为宫颈癌治疗的重要手段之一。本讨论旨在探究 DEK 原癌基因在新辅助化疗前后宫颈癌组织中的表达情况及其临床意义。通过收集 60 例宫颈癌患者的组织标本，采纳免疫组织化学方法检测 DEK 的表达情况，并统计并分析其与患者预后的关系。结果显示，新辅助化疗前，DEK 的表达率为58.3%，而新辅助化疗后表达率为 35.0%，两者之间差异有统计学意义(p<0.05)。进一步分析表明，DEK 的表达与宫颈癌患者预后相关，表达高的患者预后较差，表达低的患者预后较好。而新辅助化疗后，DEK 表达率降低，相关联的不良预后也相应降低。综上，DEK 在宫颈癌中的表达与患者预后密切相关，可作为宫颈癌的诊断和预后评估的重要指标之一，新辅助化疗能够显著降低 DEK 的表达水平，提高宫颈癌患者预后。关键词: 宫颈癌；DEK；新辅助化疗；表达水平；预后AbstractCervical cancer is one of the most common malignancies in women, and neoadjuvant chemotherapy has become an important treatment method. This study aimed to investigate the expression and clinical significance of the DEK oncogene in cervical cancer tissue before and after neoadjuvant chemotherapy. A total of 60 cervical cancer patients were included in this study, and the expression of DEK was detected by immunohistochemistry. The relationship between DEK expression and patient prognosis was analyzed.The results showed that before neoadjuvant chemotherapy, the expression rate of DEK was 58.3%, while after neoadjuvant chemotherapy, the expression rate was 35.0%, and the difference was statistically significant (p<0.05). Further analysis showed that DEK expression was related to the prognosis of cervical cancer patients. Patients with high expression had poorer prognosis, while those with low expression had better prognosis. After neoadjuvant 精品文档---下载后可任意编辑chemotherapy, the expression of DEK decreased, and the corresponding adverse prognosis also decreased.In conclusion, the expression of DEK is closely related to the prognosis of cervical cancer patients and can be used as an important indicator for the diagnosis and prognosis evaluation of cervical cancer. Neoadjuvant chemotherapy can significantly reduce the expression level of DEK and improve the prognosis of cervical cancer patients.Keywords: Cervical cancer; DEK; Neoadjuvant chemotherapy; Expression level; Prognosis
